AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Moderna's $811 Million Trading Volume Surge Despite $766 Million Contract Termination
Generated by AI AgentAinvest Volume Radar
Friday, May 30, 2025 8:46 pm ET1min read
On May 30, 2025,
(MRNA) experienced a significant trading volume of $811 million, marking a 199.49% increase from the previous day. This surge placed Moderna at the 194th position in terms of trading volume for the day. However, the stock price of Moderna closed 1.37% lower.The Trump administration has terminated a $766 million contract with Moderna, which was intended to support the development of an
vaccine for bird flu. This decision comes despite Moderna's positive interim data from a Phase I/II clinical study, which showed a robust immune response and a favorable safety profile in participants. The company is now exploring alternative paths to continue the development of its mRNA-1018 vaccine candidate.Moderna had initially received a $176 million grant from the Biomedical Advanced Research and Development Authority (BARDA) in July 2024, with an additional $590 million from the US Department of Health and Human Services (HHS), bringing the total contract value to $766 million. The funds were earmarked for the late-stage development of Moderna's mRNA-1018 vaccine, targeting the H5 influenza virus, a family of pathogens that can infect humans if transmitted from birds.
Moderna's CEO, Stéphane Bancel, expressed disappointment over the termination of funding but highlighted the positive clinical data, which underscores the potential of mRNA technology as a countermeasure to emerging health threats. The company is now considering alternative funding sources to continue the development of its bird flu vaccine.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet